Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Paper citation network

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR

Publication record · Explore literature

Public tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.

References — this paper cites (0)

No references identified in the available metadata. This does not establish that none exist.

    Cited by — these papers cite this paper (53)

    1. Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression 2026-11-01 · Expand citations
    2. Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant Depression 2026-11-01 · Expand citations
    3. Substantial Treatment-Seeking Interest, Narrow Eligibility: Diagnostic Heterogeneity and External Validity in the PRIDE Psilocybin Trial-Relevance to Precision Psychiatry 2026-10-26 · Expand citations
    4. Clinical Evidence on Psilocybin and Its Representation in Media Reporting 2026-10-20 · Expand citations
    5. The New Mexico Medical Psilocybin Act and current trends in the United States psychedelic policy 2026-10-01 · Expand citations
    6. Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review 2026-09-10 · Expand citations
    7. Beyond Efficacy Signals: Regulatory, Methodological, and Translational Challenges in Clinical Research on Ketamine and Psilocybin in Psychiatry 2026-09-01 · Expand citations
    8. PSYCHEDELICS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER AND DEPRESSION: A REVIEW OF CLINICAL TRIALS 2026-08-31 · Expand citations
    9. No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study 2026-07-23 · Expand citations
    10. Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview 2026-07-13 · Expand citations
    11. Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex 2026-06-28 · Expand citations
    12. DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish 2026-06-18 · Expand citations
    13. Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis 2026-06-15 · Expand citations
    14. Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations 2026-06-01 · Expand citations
    15. Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats 2026-06-01 · Expand citations
    16. Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial 2026-06-01 · Expand citations
    17. Psilocybin: Chemical Foundations and Emerging Therapeutic Potential 2026-06-01 · Expand citations
    18. Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial 2026-05-27 · Expand citations
    19. Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression 2026-05-15 · Expand citations
    20. The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes 2026-04-21 · Expand citations
    21. Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications 2026-04-01 · Expand citations
    22. Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies 2026-03-19 · Expand citations
    23. Explainable AI framework for psilocybin depression treatment optimization 2026-03-16 · Expand citations
    24. Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy 2026-03-01 · Expand citations
    25. A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations 2026-02-28 · Expand citations
    26. PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION 2026-01-28 · Expand citations
    27. A Comparative Neurophenomenology of the Psychedelic State and Autism: Predictive Processing as a Unifying Lens 2025-11-14 · Expand citations
    28. Classic psychedelics may treat depressive disorders, but more evidence and legislative changes are required 2025-11-04 · Expand citations
    29. Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder 2025-09-04 · Expand citations
    30. PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH 2025-09-01 · Expand citations
    31. Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report 2025-09-01 · Expand citations
    32. Is there mush-room to improve the environmental sustainability of psilocybin production? 2025-06-10 · Expand citations
    33. Psilocybin-gestützte Therapie von Depression, Angst und Suchtstörungen: Neurobiologische Grundlagen und klinische Anwendung 2025-05-01 · Expand citations
    34. Patterns of Internalizing Problems, Substance Use and Cognitive Flexibility Before and After Naturalistic Psilocybin Use: A Repeated Measures Latent Profile Analysis 2025-04-24 · Expand citations
    35. BROAD SPECTRUM OF THERAPEUTIC PROPERTIES OF PSILOCYBIN: A LITERATURE REVIEW 2025-02-20 · Expand citations
    36. “The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin 2024-10-29 · Expand citations
    37. Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine-A Systematic Review and Meta-Analysis 2024-10-03 · Expand citations
    38. Change in occupational burnout measures in emergency medical service workers after a psychedelic experience induced by a single self-administered dose of psilocybin mushrooms 2024-09-09 · Expand citations
    39. Resurrecting Ancestral Familial Health: A Role for Psilocybin? 2024-08-09 · Expand citations
    40. Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry 2024-02-01 · Expand citations
    41. Psilocybin and eugenol prevent DSS-induced neuroinflammation in mice 2024-01-25 · Expand citations
    42. How should psychotherapy proceed when adjoined with psychedelics? 2024-01-12 · Expand citations
    43. Psychedelic Mushrooms: The Use of Psilocybin in the Treatment of Mental Disorders 2024-01-01 · Expand citations
    44. Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: A feasibility study protocol 2023-10-25 · Expand citations
    45. Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training 2023-09-08 · Expand citations
    46. Psilocybin's Emerging Role in Combating Depressive Disorder 2023-08-08 · Expand citations
    47. A regulatory framework review of Schedule I psychedelics in the United States 2023-06-12 · Expand citations
    48. Psilocybin therapy: A novel approach to treating depression 2023-06-02 · Expand citations
    49. A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history 2023-04-26 · Expand citations
    50. From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia 2022-12-31 · Expand citations
    51. The psychedelic escape from depression 2022-09-27 · Expand citations
    52. Psychedelics in the Treatment of Substance Use Disorders 2022-09-01 · Expand citations
    53. Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions 2022-06-09 · Expand citations